Psychopharmacology in dermatology

Dermatologic Therapy

Volumn 21, Issue 1, 2008, Pages 69-82

  Lee, Chai Sue ^a   Accordino, Robert ^b   Howard, Josephine ^c   Koo, John ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Psychocutaneous medicine; Psychodermatology

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTAZOLINE; BENZATROPINE MESILATE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; DESIPRAMINE; DIPHENHYDRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; GABAPENTIN; HYDROXYZINE; IMIPRAMINE; LORAZEPAM; OLANZAPINE; PAROXETINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANOREXIA; ANTICHOLINERGIC EFFECT; ANXIETY; BEDTIME DOSAGE; BLURRED VISION; CONSTIPATION; DELUSION; DEPRESSION; DIAPHORESIS; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG CHOICE; DRUG DEPENDENCE; DRUG DOSE TITRATION; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; LOW DRUG DOSE; MALAISE; METABOLIC SYNDROME X; MUSCLE STIFFNESS; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSESSIVE COMPULSIVE DISORDER; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PRURITUS; PSYCHOCUTANEOUS DISEASE; PSYCHODYNAMICS; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; QT PROLONGATION; REBOUND; RESTLESSNESS; REVIEW; RHINITIS; RISK FACTOR; SEDATION; SEIZURE SUSCEPTIBILITY; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; URINARY HESITANCY; URINE RETENTION; VIVID DREAM; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; SKIN DISEASES;

EID: 40349087423     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.00172.x     Document Type: Review

References (51)

1. Haskins JT, Aguilar L, Pallay A, et al. for the Venalafaxine XR 210 Study Group. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder [abstract ]. Presented at the 11th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France.
2. Haskins JT, Rudolph R, Aguiar L, et al. for the Venlafaxine XR 214 Study Group. Double-blind, placebo-comparator-controlled study of once daily venlafaxine XR and buspirone in outpatients with generalized anxiety disorder [abstract]. Presented at the 11th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France.
3. Haskins JT, Rudolph R, Aguiar L, et al. for the Venlafaxine XR 218 Study Group. Venlafaxine XR is an efficacious short- and long-term treatment for generalized anxiety disorder [abstract]. Presented at the 11th Congress of the European College of Neuropychopharmacology; Oct 31-Nov 4, 1998; Paris, France.
4. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of gerneralized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001 : 62 : 350 357.
5. Haskell DS, Gambill JD, Gardos G, McNair DM, Fisher S. Doxepin or diazepam for anxious and anxious-depressed outpatients? J Clin Psychiatry 1978 : 39 : 135 139.
6. Friedel RO, Raskind MA. Relationship of blood levels of Sinequan to clinical effects in the treatment of depression in aged patients. In : Mendels J, ed. A monograph of recent clinical studies. Lawrenceville, NJ : Excerpta Medica, 1975.
7. Settle EC Jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998 : 59 (Suppl. 16 25 30.
8. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993 : 54 : 119 126.
9. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994 : 9 : 139 143.
10. Lecrubier Y, Bourin M, Moon CAL, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997 : 95 : 485 493.
11. Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994 : 14 : 322 329.
12. Silverstone PH, Ravindran A for the Venlafaxine XR 360 Canadian Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999 : 60 : 22 28.
13. Haskins JT, Aguiar L, Pallay A, et al. for the Venlafaxine XR 210 Study Group. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (abstract). Presented at the 11th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France.
14. Haskins JT, Rudolph R, Aguiar L, et al. for the Venlafaxine XR 210 Study Group. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (abstract). Presented at the 11th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France.
15. Haskins JT, Rudolph R, Aguiar L, et al. for the Venlafaxine XR 218 Study Group. Venlafaxine XR is an efficacious short- and long-term treatment for generalized anxiety disorder (abstract). Presented at the 11th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France.
16. Modell JG, Katholi CR, Modell JD, et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997 : 61 : 476 487.
17. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997 : 58 : 532 537.
18. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991 : 52 (Suppl 4 10.
19. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989 : 50 : 256 261.
20. Munro A. Monosymptomatic hypochondriacal psychosis. Br J Psychiatry 1988 : 153 (Suppl 37 40.
21. Munro A, Chmars J. Monosymptomatic hypochondriacal psychosis: a diagnostic checklist based on 50 cases of the disorder. Can J Psychol 1982 : 27 : 374 376.
22. Bishop ER Jr. Monosymptomatic hypochondriacal syndromes in dermatology. J Am Acad Dermatol 1983 : 9 : 152 158.
23. Damiani JT, Flowers FP, Pierce DK. Pimozide in delusions of parasitosis. J Am Acad Dermatol 1990 : 22 : 312 313.
24. Hamann K, Avnstorp L. Delusions of infestation treated by pimozide: a double-blind crossover clinical study. Acta Derm Venereol (Stockh) 1982 : 62 : 55 58.
25. Holmes VF. Treatment of monosymptomatic hypochondriacal psychosis with pimozide in an AIDS patient (letter). Am J Psychiatry 1989 : 146 : 554 555.
26. Lindskov R. Delusions of infestations treated with pimozide. Acta Derm Venereol 1985 : 65 : 267 270.
27. Driscoll MS, Rothe MJ, Grant-Kels JM, Hale MS. Delusional parasitosis: a dermatologic psychiatric and pharmacologic approach. JAAD 1993 : 29 : 1023 1033.
28. Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology, 3rd edn. Washington DC : APA Press, 1997 : 154 155.
29. Meltzer HY. New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993 : 16 : 365 385.
30. Deutch AY, Moghaddam B, Innis RB, et al. Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991 : 4 : 121 156.
31. Gerlach J. New antipsychotics: classifications, efficacy and adverse effects. Schizophr Bull 1991 : 17 : 289 309.
32. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991 : 148 : 1474 1486.
33. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993 : 54 (Suppl 13 17.
34. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996 : 57 (Suppl. 11 40S 45S.
35. Prescribing information. Risperdal (risperidone). Titusville, NJ : Janssen Pharmaceutica, 1996.
36. De Leon OA, Furmaga KM, Canerbury AL, Bailey LG. Risperidone in the treatment of delusions of infestation. Int J Psychiatry Med 1997 : 27 : 403 409.
37. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull 1997 : 23 : 567 582.
38. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997 : 58 (Suppl. 14 39 45.
39. Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 1997 : 58 (Suppl. 13 9 13.
40. Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982 : 32 : 671 673.
41. Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988 : 38 : 1427 1432.
42. Watson CPN, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind crossover trial. Pain 1992 : 48 : 29 36.
43. Feinmann C, Harris M, Cawley R. Psychogenic facial pain: presentation and treatment. Br Med J 1984 : 288 : 436 438.
44. Urban BJ, France FD, Maltbie AA, et al. Long-term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain 1986 : 24 : 191 196.
45. Eberhard G, von Knorring L, Nilsson HL, et al. A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes. Neuropsychobiology 1988 : 19 : 25 34.
46. Bernstein JE, Whitney DH, Soltani K. Inhibition of histamine-induced pruritus by topical tricyclic antidepressants. J Am Acad Dermatol 1981 : 5 : 582 585.
47. Savin JA, Paterson WD, Adam K, et al. Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. Arch Dermatol 1979 : 115 : 313 315.
48. Figueiredo A, Ribeiro CA, Goncalo M, et al. Mechanism of action of doxepin in the treatment of chronic urticaria. Fund Clin Pharmacol 1990 : 4 : 147 158.
49. Lawlor F, Greaves MW. The development of recent strategies in the treatment of urticaria as a result of clinically oriented research. Zeitschrift fur Hautkrankheiten 1990 : 65 : 17 27.
50. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990 : 47 : 305 312.
51. Boyer WI. Potential indications for the selective serotonin reuptake inhibitors. Int J Clin Psychopharmacol 1992 : 6 (Suppl. 5 5 12.